Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime–Avibactam Combination: A Model-Informed Strategy for its Clinical Development

Avibactam Pharmacokinetic/Pharmacodynamic Targets

(2018) Wright W. Nichols et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A mathematical model-based analysis of the time–kill kinetics of ceftazidime/avibactam against Pseudomonas aeruginosa

(2018) Sherwin K B Sy et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial

(2018) Antoni Torres et al.   LANCET INFECTIOUS DISEASES

A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia

(2017) Xinyu Qin et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Fluoroquinolone resistance in extended-spectrum β-lactamase-producing Klebsiella pneumoniae in a Japanese tertiary hospital: silent shifting to CTX-M-15-producing K. pneumoniae

(2017) Masashi Higashino et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients

(2016) John S. Bradley et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae

(2016) James Albiero et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroSusceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014)

(2016) Wright W. Nichols et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program

(2016) Florian M. Wagenlehner et al.   CLINICAL INFECTIOUS DISEASES

Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society

(2016) Andre C. Kalil et al.   CLINICAL INFECTIOUS DISEASES

Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program

(2016) John E. Mazuski et al.   CLINICAL INFECTIOUS DISEASES

Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia

(2016) Vicenç Falcó et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

In vitropharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms

(2016) Sherwin K. B. Sy et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment

(2016) Henri Merdjan et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study

(2016) Yehuda Carmeli et al.   LANCET INFECTIOUS DISEASES

Antimicrobial Resistance in the Intensive Care Unit

(2016) Shawn H. MacVane   JOURNAL OF INTENSIVE CARE MEDICINE

Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection

(2015) Johanna Berkhout et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroAntibacterial Activity of the Ceftazidime-Avibactam Combination against Enterobacteriaceae, Including Strains with Well-Characterized β-Lactamases

(2015) Premavathy Levasseur et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Avibactam Alone and in Combination with Ceftazidime in Healthy Male Volunteers: Results of Two Randomized, Placebo-Controlled Studies

(2015) Henri Merdjan et al.   CLINICAL DRUG INVESTIGATION

Effect of Age and Sex on the Pharmacokinetics and Safety of Avibactam in Healthy Volunteers

(2015) Antoine Tarral et al.   CLINICAL THERAPEUTICS

Pharmacokinetics and pharmacodynamics in antibiotic dose optimization

(2015) Sherwin KB Sy et al.   Expert Opinion on Drug Metabolism & Toxicology

Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens

(2015) David P. Nicolau et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The β-Lactams Strike Back: Ceftazidime-Avibactam

(2015) Evan J. Zasowski et al.   PHARMACOTHERAPY

Ceftazidime–avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections

(2015) Yogesh Mawal et al.   Expert Review of Clinical Pharmacology

In VitroActivity of Ceftazidime-Avibactam Combination inIn VitroCheckerboard Assays

(2014) Johanna Berkhout et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activities of Ceftazidime and Avibactam against β-Lactamase-Producing Enterobacteriaceae in a Hollow-Fiber Pharmacodynamic Model

(2014) Ken Coleman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012)

(2014) R. K. Flamm et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Multistate Point-Prevalence Survey of Health Care–Associated Infections

(2014) Shelley S. Magill et al.   NEW ENGLAND JOURNAL OF MEDICINE

In VitroActivities of Ceftazidime-Avibactam and Aztreonam-Avibactam against 372 Gram-Negative Bacilli Collected in 2011 and 2012 from 11 Teaching Hospitals in China

(2013) Xiaojuan Wang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Systematic Review and Meta-Analysis of Antimicrobial Treatment Effect Estimation in Complicated Urinary Tract Infection

(2013) Krishan P. Singh et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacies of Ceftazidime-Avibactam and Ceftazidime against Pseudomonas aeruginosa in a Murine Lung Infection Model

(2013) Seth T. Housman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Structural Insight into Potent Broad-Spectrum Inhibition with Reversible Recyclization Mechanism: Avibactam in Complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-Lactamases

(2013) Sushmita D. Lahiri et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Contemporary Diversity of β-Lactamases among Enterobacteriaceae in the Nine U.S. Census Regions and Ceftazidime-Avibactam Activity Tested against Isolates Producing the Most Prevalent β-Lactamase Groups

(2013) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Organisms Collected from U.S. Medical Centers in 2012

(2013) Helio S. Sader et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial

(2013) Christopher Lucasti et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value

(2013) Robert K. Flamm et al.   JOURNAL OF CHEMOTHERAPY

Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam

(2013) Shampa Das et al.   JOURNAL OF CLINICAL PHARMACOLOGY

ComparativeIn VitroandIn VivoEfficacies of Human Simulated Doses of Ceftazidime and Ceftazidime-Avibactam against Pseudomonas aeruginosa

(2012) Jared L. Crandon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroAntibacterial Activity of the Ceftazidime-Avibactam (NXL104) Combination against Pseudomonas aeruginosa Clinical Isolates

(2012) Premavathy Levasseur et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study

(2012) José A. Vazquez et al.   CURRENT MEDICAL RESEARCH AND OPINION

Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia

(2012) A. E. Muller et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In VitroActivity of Ceftazidime-NXL104 against 396 Strains of β-Lactamase-Producing Anaerobes

(2011) Diane M. Citron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of Ceftazidime Combined with NXL104 versus Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals (CANWARD 2009 Study)

(2011) A. Walkty et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach

(2011) J.W. Mouton et al.   CLINICAL MICROBIOLOGY AND INFECTION

Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors

(2011) Ken Coleman   CURRENT OPINION IN MICROBIOLOGY

In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae

(2011) Z. Aktaş et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non- -Lactam  -Lactamase Inhibitor

(2010) T. Stachyra et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population Pharmacokinetic Comparison and Pharmacodynamic Breakpoints of Ceftazidime in Cystic Fibrosis Patients and Healthy Volunteers

(2010) J. B. Bulitta et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Microbial Etiologies of Hospital‐Acquired Bacterial Pneumonia and Ventilator‐Associated Bacterial Pneumonia

(2010) Ronald N. Jones   CLINICAL INFECTIOUS DISEASES

Current Challenges in Antimicrobial Chemotherapy

(2010) Carine Bebrone et al.   DRUGS

In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters

(2010) S. Mushtaq et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Updated Functional Classification of  -Lactamases

(2009) K. Bush et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Diagnosis and Management of Complicated Intra‐abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America

(2009) Joseph S. Solomkin et al.   CLINICAL INFECTIOUS DISEASES

In vitro activity of the  -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases

(2009) T. Stachyra et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum  -lactamases and carbapenemases

(2008) D. M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY